



Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease

C. Requejo¹ · J. A. Ruiz-Ortega² · H. Bengoetxea¹ · S. Bulnes¹ · L. Ugedo² · J. V. Lafuente^{1,3,4}

Published online: 5 March 2018

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: Mol Neurobiol

<https://doi.org/10.1007/s12035-017-0733-x>

The authors found a terrible mistake in the manuscript. The legends from the Figs. 5 and 6 are interchanged.

The Fig. 5 should be appeared with the legend from the Fig.6 and Fig. 6 should be appeared with the legend from the Fig. 5.

In addition, the authors also found in the Fig. 6 a mistake in the text referring to the order for (a,b,c,d). Please, find below the correct legend for every figure.

Fig. 5 Vandetanib administration induced activation of caspase-3. The vandetanib group showed significantly increased expression of caspase-3 relative to the control group in the striatum (**a, c**) and in the substantia nigra (**b, d**) ($*P \leq 0.05$)

Fig. 6 Molecular changes in survival pathways after vandetanib administration. No differences were found in the activation of Akt (**a, b**) or ERK1/2 (**c, d**) in the vandetanib group relative to the control group

The online version of the original article can be found at <https://doi.org/10.1007/s12035-017-0733-x>

✉ C. Requejo
catalina.requejo@ehu.eus

¹ LaNCE, Department of Neuroscience, University of the Basque, Country (UPV/EHU), Vizcaya, Leioa, Spain

² Department of Pharmacology, University of the Basque Country, (UPV/EHU), Vizcaya, Leioa, Spain

³ Nanoneurosurgery Group, BioCruces Health Research Institute, 48903 Barakaldo, Bizkaia, Spain

⁴ Faculty of Health Science, Universidad Autónoma de Chile, Santiago de Chile, Chile